Apogee Therapeutics, a San Francisco, CA-based biotechnology company, raised $149M in Series B funding.
The round was co-led by Deep Track Capital and RTW Investments.
The company, which emerged with $169m, intends to use the funds to support key leadership, science, and clinical team hires and progress its lead pipeline program, APG777, to the clinic in 2023.
Founded by Fairmount and Venrock Healthcare Capital Partners and led by CEO Michael Henderson, M.D., Apogee Therapeutics is a biotechnology company advancing therapies to address the needs of people living with immunological and inflammatory disorders. The company is building a pipeline of product candidates targeting clinically validated biology and well-established development pathways.
Apogee is the first spinout of Paragon Therapeutics, a biotechnology company leveraging science and technology to identify and propel biologics into the clinic for a range of human diseases with high unmet needs. The company advances therapies through a range of opportunities, from new company creation and strategic partnerships to shaping programs in-house.
FinSMEs
12/12/2022